Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Latanoprostene bunod (LBN) demonstrated significant reductions in intraocular pressure (IOP), outperforming unoprostone by -3.45 mm Hg and numerically exceeding latanoprost (-0.70 mm Hg) and tafluprost (-0.41 mm Hg). It was similar to bimatoprost 0.01% (-0.02 mm Hg) and slightly less effective than bimatoprost 0.03% (-0.17 mm Hg).
• LBN was significantly more effective in reducing IOP compared to beta-blockers, including apraclonidine, betaxolol, brimonidine, brinzolamide, carteolol, dorzolamide, and timolol.
• There was no difference between medical therapies, including LBN, and placebo or no treatment in terms of visual acuity, quality of life, or functional outcomes.
• Recently approved glaucoma therapies, including LBN, were associated with an increased risk of adverse events compared to older therapies, though no specific numerical data for LBN alone were provided.
• There is no further safety information specific to LBN detailed in the reviewed studies.
• There is no population types or subgroups information available in the reviewed studies.